The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Dupilumab for treatment of atopic dermatitis
Abstract
INTRODUCTION: Dupilumab is a new treatment option for patients with moderate-to-severe atopic dermatitis. It blocks IL-4/IL13-signaling and thereby inhibits receptor signaling downstream the JAK-STAT-pathway. Three of the main disease mechanisms of atopic dermatitis are affected by blocking this pathway; the decrease of skin barrier function, the class switch to IgE and the TH2-differentiation. Areas Covered: Dupilumab showed promising results in clinical trials of phase I-III. Clinical outcome parameters such as SCORAD, EASI, IGA and BSA improved with dupilumab. A positive effect on patient-reported outcomes like DLQI or pruritus-rating-scales was also demonstrated. The safety profile of dupilumab is superior to conventional immunosuppressive drugs, such as cyclosporine or methotrexate. Injection-site reactions and conjunctivitis were the most relevant side-effects. Skin infections were less frequently observed compared to placebo. Data on the use of dupilumab during pregnancy or in children are not published to date. Expert Commentary: Dupilumab was approved by the FDA in April 2017 for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“inadequately controlled by topical treatment [59].”
Self-citationAnti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Self-citationPopovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., Spooner, J., Keen, J., Minter, R., Uddin, F., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.005 · Cited by 198 · cited 1×
“The IL-13 neutralizing antibody tralokinumab inhibits the interaction of IL-13 with the IL-13R-alpha receptor subunits [67].”
BackgroundQuality of life of children with atopic dermatitis and their families
McKenna, S. P., & Doward, L. C. (2008) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0b013e3282ffd6cc · Cited by 74
Cited by
Halling, A.-S., Loft, N., Silverberg, J. I., Guttman-Yassky, E., & Thyssen, J. P. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.08.051 · Cited by 288
Recent advancements in the atopic dermatitis mechanism
Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902084 · Cited by 53
Metadata
- Authors
- Seegräber, M., Srour, J., Walter, A., Knop, M., & Wollenberg, A.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2018-03-20
- Volume
- 11
- Issue
- 5
- Pages
- 467-474
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2793866333
- Cited by
- 222
- References
- 4
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dupilumab for treatment of atopic dermatitis. https://app.cochat.ai/papers/10.1080/17512433.2018.1449642
- The paper
- Seegräber, M., Srour, J., Walter, A., Knop, M., & Wollenberg, A. (2018). Dupilumab for treatment of atopic dermatitis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2018.1449642
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.